218 related articles for article (PubMed ID: 24698059)
1. Ethical dilemmas about orphan drugs for orphan diseases.
Isaacs D
J Paediatr Child Health; 2014 Apr; 50(4):249-50. PubMed ID: 24698059
[No Abstract] [Full Text] [Related]
2. Ethical dilemmas about orphan drugs for orphan diseases.
Gunasekera H
J Paediatr Child Health; 2014 Aug; 50(8):656. PubMed ID: 25080986
[No Abstract] [Full Text] [Related]
3. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
4. Ethical considerations in orphan drug approval and use.
Kesselheim AS
Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
[TBL] [Abstract][Full Text] [Related]
5. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
6. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
7. Orphan economics: the downside of supplyside pharmacology.
Samson K
Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
[No Abstract] [Full Text] [Related]
8. Policymaking for Orphan Drugs and Its Challenges.
Rhee TG
AMA J Ethics; 2015 Aug; 17(8):776-9. PubMed ID: 26270879
[No Abstract] [Full Text] [Related]
9. Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium.
Picavet E; Cassiman D; Pinxten W; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):571-3. PubMed ID: 24138643
[TBL] [Abstract][Full Text] [Related]
10. Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers.
Ollendorf DA; Chapman RH; Pearson SD
Value Health; 2018 May; 21(5):547-552. PubMed ID: 29753351
[TBL] [Abstract][Full Text] [Related]
11. Our moral obligations in caring for patients with orphan cancers.
Fernandez CV
CMAJ; 2007 Jan; 176(3):297, 299. PubMed ID: 17261816
[No Abstract] [Full Text] [Related]
12. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
13. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
14. Orphan drugs and the NHS: consider whom drug regulation is designed to protect.
Marshall T
BMJ; 2005 Nov; 331(7525):1144. PubMed ID: 16282417
[No Abstract] [Full Text] [Related]
15. [Orphan drugs: towards an economic evaluation].
Holué C
Rev Prat; 2012 Jan; 62(1):91-4. PubMed ID: 22335077
[No Abstract] [Full Text] [Related]
16. [Drugs for rare diseases].
Rolfs M; Lindemalm S
Lakartidningen; 2010 Apr 21-27; 107(16):1043. PubMed ID: 20476696
[No Abstract] [Full Text] [Related]
17. The management of rare diseases.
Walshe JM
Clin Med (Lond); 2005; 5(1):81-2. PubMed ID: 15745209
[No Abstract] [Full Text] [Related]
18. Orphan drug policies and use in pediatric nephrology.
Karpman D; Höglund P
Pediatr Nephrol; 2017 Jan; 32(1):1-6. PubMed ID: 27738765
[TBL] [Abstract][Full Text] [Related]
19. [Orphan drugs: availability, reliability and reimbursement].
Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
[TBL] [Abstract][Full Text] [Related]
20. How can the risk that orphan drugs present to budgets be managed better?
O'Neill C
Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
[No Abstract] [Full Text] [Related]
[Next] [New Search]